Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 11/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178297 | 1.00 | TBXAS1 (0.64) | TBXAS1TDP1L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL10622938 | 0.96 | TBXAS1 (0.57) | TBXAS1TDP1L3MBTL1CYP4Z1ALDH1A1 | |
| Bromide SCHEMBL28464116 | 0.91 | TDP1 (0.58) | TBXAS1TDP1L3MBTL1 | |
| SCHEMBL3957320 | 0.90 | CYP4F2 (0.55) | TBXAS1TDP1L3MBTL1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL27552763 | 0.88 | CYP4F2 (0.54) | TBXAS1TDP1L3MBTL1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL18230734 | 0.88 | CYP4F2 (0.54) | TBXAS1TDP1L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL10972402 | 0.85 | TBXAS1 (0.68) | TBXAS1TDP1L3MBTL1CHRNA7HRH1 | |
| SCHEMBL6642146 | 0.84 | TBXAS1 (0.68) | TBXAS1TDP1L3MBTL1CHRNA7HRH1 | |
| SCHEMBL6642413 | 0.84 | TBXAS1 (0.68) | TBXAS1TDP1L3MBTL1CHRNA7HRH1 | |
| SCHEMBL27622791 | 0.82 | CHRNA7 (0.61) | TBXAS1TDP1L3MBTL1CHRNA7HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115623-B2 | PDE IV inhibitors | ASKA PHARMACEUTICALS CO., LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| CN-1224624-C | 1, 8-naphthyridin-2 (1H) -one derivatives | GRELAN PHARMACEUTICAL CO (JP) | 2005-10-26 | — | — | CN | disclosed |
| US-20040176365-A1 | Pde IV inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1403270-A1 | PDE IV INHIBITORS | Grelan Pharmaceutical Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1236725-B1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | GRELAN PHARMACEUTICAL CO (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6642250-B2 | As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| CN-1407984-A | Novel 1, 8-naphthyridin-2 (1H) -one derivatives | GRELAN PHARMACEUTICAL CO (JP) | 2003-04-02 | — | — | CN | disclosed |
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-02-20 | — | — | US | disclosed |
| EP-1236725-A1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | Grelan Pharmaceutical Co., Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-5103007-A | Antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5081245-A | Selective antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0378763-A1 | Lipids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-07-25 | — | — | EP | disclosed |
| EP-0356765-A2 | Carboxylic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176365-A1 | Pde IV inhibitors | PDE3B, PDE3A, PDE2A | TBXAS1 169/4885TDP1 876/4885L3MBTL1 4199/4885 |
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | PDE3B, PDE4A, PDE4B | TBXAS1 89/4885TDP1 450/4885L3MBTL1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.